Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Voyager Therapeutics (VYGR) EBIT Margin: 2015-2025

Historic EBIT Margin for Voyager Therapeutics (VYGR) over the last 11 years, with Sep 2025 value amounting to -228.31%.

  • Voyager Therapeutics' EBIT Margin fell 17236.00% to -228.31% in Q3 2025 from the same period last year, while for Sep 2025 it was -446.84%, marking a year-over-year decrease of 45239.00%. This contributed to the annual value of -104.11% for FY2024, which is 15291.00% down from last year.
  • Latest data reveals that Voyager Therapeutics reported EBIT Margin of -228.31% as of Q3 2025, which was up 67.58% from -704.33% recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' EBIT Margin registered a high of 1,584.71% during Q4 2022, and its lowest value of -3,244.68% during Q1 2022.
  • Moreover, its 3-year median value for EBIT Margin was -228.31% (2025), whereas its average is -298.43%.
  • In the last 5 years, Voyager Therapeutics' EBIT Margin slumped by 285,106bps in 2022 and then spiked by 332,634bps in 2023.
  • Quarterly analysis of 5 years shows Voyager Therapeutics' EBIT Margin stood at 20.31% in 2021, then skyrocketed by 156,440bps to 1,584.71% in 2022, then slumped by 152,468bps to 60.03% in 2023, then crashed by 67,008bps to -610.05% in 2024, then tumbled by 17,236bps to -228.31% in 2025.
  • Its EBIT Margin stands at -228.31% for Q3 2025, versus -704.33% for Q2 2025 and -533.74% for Q1 2025.